WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Earnings & Revenue

ALNY past revenue growth

How has ALNY's revenue growth performed historically?
Company
76.23%
Industry
187.71%
Market
18.28%
ALNY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ALNY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ALNY's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ALNY earnings and revenue history

Current Revenue
$1.8B
Current Earnings
-$440.2M
Current Profit Margin
-24.1%

ALNY Return on Equity

Current Company
N/A
Current Industry
-68.1%
Current Market
188%

Be the first to know when ALNY announces earnings.

ALNY Return on Assets

Current Company
-12.2%
Current Industry
9.2%
ALNY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ALNY Return on Capital Employed

Current Company
-10.91%
Current Industry
27.7%
ALNY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ALNY vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ALNY$1.83B-$215.27M-$440.24M+89.45%N/A
BGNE$2.46B-$812.17M-$881.71M+65.47%N/A
RPRX$2.35B$1.32B$1.13B+5.58%+97.41%
GMAB$2.40BN/A$633.48M+39.38%+21.77%
BNTX$6.97B$4.23B$2.90B+158.10%-42.30%

Alnylam Pharmaceuticals Earnings & Revenue FAQ

What were ALNY's earnings last quarter?

On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2023 earnings per share (EPS) of -$1.09, up 35.12% year over year. Total Alnylam Pharmaceuticals earnings for the quarter were -$137.87 million. In the same quarter last year, Alnylam Pharmaceuticals's earnings per share (EPS) was -$1.68.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.

What was ALNY's earnings growth in the past year?

As of Q1 2024, Alnylam Pharmaceuticals's earnings has grown year over year. Alnylam Pharmaceuticals's earnings in the past year totalled -$440.24 million.

What was ALNY's revenue last quarter?

On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2023 revenue of $439.72 million up 31.25% year over year. In the same quarter last year, Alnylam Pharmaceuticals's revenue was $335.04 million.

What was ALNY's revenue growth in the past year?

As of Q1 2024, Alnylam Pharmaceuticals's revenue has grown 76.23% year over year. This is 111.48 percentage points lower than the US Biotechnology industry revenue growth rate of 187.71%. Alnylam Pharmaceuticals's revenue in the past year totalled $1.83 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.